EVerMed Secures Investment from Nissay Capital
Deal News | Jan 28, 2025 | Nissay Capital Co Ltd
Nissay Capital Co Ltd., a private equity firm, has announced its investment in EVerMed, a company specializing in extracellular vesicle technology. The investment aligns with Nissay Capital's strategy to back innovative companies in the biotech sector. EVerMed is making strides in the development and application of extracellular vesicles, which have significant potential in therapeutic and diagnostic processes. Through this investment, EVerMed aims to enhance its research capabilities and bring advanced solutions to market. The collaboration represents a step forward in broadening the scope and impact of biotechnology innovations.
Sectors
- Biotechnology
- Private Equity
Geography
- Japan – Both Nissay Capital and EVerMed are based in Japan, indicating the geographic focus of the investment.
Industry
- Biotechnology – The sector focuses on technological and scientific advancements in biology, relevant due to EVerMed's work with extracellular vesicles.
- Private Equity – Nissay Capital's involvement highlights the role of private equity in funding innovative biotech companies.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EVerMed | Target Company | Company | A biotech firm specializing in extracellular vesicle technology. |
| Nissay Capital Co Ltd. | Investor | Company | A private equity firm providing investment support to EVerMed. |